title: Quantitative assessment of hematopoietic chimerism after allogeneic bone marrow transplantation has predictive value for the occurrence of irreversible graft failure and graft-vs.-host disease.
abstract: Primary graft failure, secondary to either host-vs.-graft reaction or delayed engraftment, and graft-vs.-host disease (GVHD) are among the most difficult clinical problems to manage in the field of allogeneic bone marrow transplantation (BMT). Early diagnosis of both conditions would greatly improve their outcome. Using fluorescence in situ hybridization (FISH) with an X- and Y-probe mixture, we sequentially monitored chimerism of neutrophils and lymphoid cells from day 1 to 100 in 28 consecutive recipients of sex-mismatched unmanipulated bone marrow grafts. The objective was to quantitatively assess the evolution of chimerism during this crucial time interval and to determine whether chimerism patterns would be predictive of engraftment and GVHD. In recipients with primary graft failure (n=7), the presence of donor-type neutrophils and NK cells as well as the predominance of donor-type T cells distinguished patients who responded to G-CSF (n=5) from nonresponders (n=2). Furthermore, the clearance of host CD3+CD56- cells during days 5-10 posttransplantation was significantly hastened in patients who subsequently developed acute (delta=80%) or chronic (delta=81%) GVHD compared with patients without GVHD (delta=17%). Thus, our data suggest that molecular monitoring of the fate of host/donor hematopoietic cells in the early posttransplantation period could be useful in differentiating patients with delayed engraftment from those with irreversible rejection and in predicting the occurrence of GVHD as soon as day 10. This investigational approach may provide an appropriate basis on which to select adequate treatment for primary graft failure and high-risk candidates that could benefit from novel preemptive therapies for GVHD.
authors.affiliation: Department of Hematology and Research Center, Maisonneuve-Rosemont Hospital, University of Montreal, Quebec, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Gyger
authors.forename: C
authors.initials: C
authors.lastname: Baron
authors.forename: L
authors.initials: L
authors.lastname: Forest
authors.forename: P
authors.initials: P
authors.lastname: Lussier
authors.forename: F
authors.initials: F
authors.lastname: Lagacé
authors.forename: I
authors.initials: I
authors.lastname: Bissonnette
authors.forename: R
authors.initials: R
authors.lastname: Bélanger
authors.forename: Y
authors.initials: Y
authors.lastname: Bonny
authors.forename: L
authors.initials: L
authors.lastname: Busque
authors.forename: D C
authors.initials: DC
authors.lastname: Roy
authors.forename: C
authors.initials: C
authors.lastname: Perreault
mesh_terms: D016026:Bone Marrow Transplantation / Q000276:immunology; D004247:DNA / Q000032:analysis; D006084:Graft Rejection / Q000453:epidemiology* / Q000209:etiology; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D012737:Sex Factors; D018183:Transplantation Chimera / Q000235:genetics / Q000502:physiology*; D014184:Transplantation, Homologous
chemical_list: D004247:DNA